These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17171733)

  • 1. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.
    Failes TW; Cullinane C; Diakos CI; Yamamoto N; Lyons JG; Hambley TW
    Chemistry; 2007; 13(10):2974-82. PubMed ID: 17171733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids.
    Failes TW; Hambley TW
    Dalton Trans; 2006 Apr; (15):1895-901. PubMed ID: 16585977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat.
    Failes TW; Hambley TW
    J Inorg Biochem; 2007 Mar; 101(3):396-403. PubMed ID: 17197030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of cobalt(III) hydroxamic acid complexes based on a tris(2-pyridylmethyl)amine scaffold: reactivity toward cysteine methyl ester.
    Alimi M; Allam A; Selkti M; Tomas A; Roussel P; Galardon E; Artaud I
    Inorg Chem; 2012 Sep; 51(17):9350-6. PubMed ID: 22905650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization and biological activities of mononuclear Co(III) complexes as potential bioreductively activated prodrugs.
    Souza ET; Castro LC; Castro FA; do Canto Visentin L; Pinheiro CB; Pereira MD; de Paula Machado S; Scarpellini M
    J Inorg Biochem; 2009 Oct; 103(10):1355-65. PubMed ID: 19665800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia-selective cytotoxins.
    Perrin LC; Wilson WR; Denny WA; McFadyen WD
    Anticancer Drug Des; 1999 Jun; 14(3):231-41. PubMed ID: 10500498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs.
    Chang JY; Lu GL; Stevenson RJ; Brothers PJ; Clark GR; Botting KJ; Ferry DM; Tercel M; Wilson WR; Denny WA; Ware DC
    Inorg Chem; 2013 Jul; 52(13):7688-98. PubMed ID: 23773210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
    Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA
    Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of metal ions and Marimastat with matrix metalloproteinase 9.
    Underwood CK; Min D; Lyons JG; Hambley TW
    J Inorg Biochem; 2003 Jun; 95(2-3):165-70. PubMed ID: 12763661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lawsone dimerization in cobalt(III) complexes toward the design of new prototypes of bioreductive prodrugs.
    Bustamante FL; Metello JM; de Castro FA; Pinheiro CB; Pereira MD; Lanznaster M
    Inorg Chem; 2013 Feb; 52(3):1167-9. PubMed ID: 23343393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
    Steward WP; Thomas AL
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2913-22. PubMed ID: 11093361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of [(P)M-(X)-Co(TMPA)]n+ assemblies; P = Porphyrinate, M = FeIII and CoIII, X = O2-, OH-, O2(2-), and TMPA = tris(2-pyridylmethyl)amine.
    Chufan EE; Verani CN; Puiu SC; Rentschler E; Schatzschneider U; Incarvito C; Rheingold AL; Karlin KD
    Inorg Chem; 2007 Apr; 46(8):3017-26. PubMed ID: 17371009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease.
    Treharne GD; Boyle JR; Goodall S; Loftus IM; Bell PR; Thompson MM
    Br J Surg; 1999 Aug; 86(8):1053-8. PubMed ID: 10460642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies.
    O'Neill ES; Kaur A; Bishop DP; Shishmarev D; Kuchel PW; Grieve SM; Figtree GA; Renfrew AK; Bonnitcha PD; New EJ
    Inorg Chem; 2017 Aug; 56(16):9860-9868. PubMed ID: 28766939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox activity and two-step valence tautomerism in a family of dinuclear cobalt complexes with a spiroconjugated bis(dioxolene) ligand.
    Alley KG; Poneti G; Robinson PS; Nafady A; Moubaraki B; Aitken JB; Drew SC; Ritchie C; Abrahams BF; Hocking RK; Murray KS; Bond AM; Harris HH; Sorace L; Boskovic C
    J Am Chem Soc; 2013 Jun; 135(22):8304-23. PubMed ID: 23663158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrophosphate-bridged complexes with picomolar toxicity.
    Ikotun OF; Higbee EM; Ouellette W; Doyle RP
    J Inorg Biochem; 2009 Sep; 103(9):1254-64. PubMed ID: 19666193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
    Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
    Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the ancillary ligand on the potential of cobalt(iii) complexes to act as chaperones for hydroxamic acid-based drugs.
    Green BP; Renfrew AK; Glenister A; Turner P; Hambley TW
    Dalton Trans; 2017 Nov; 46(45):15897-15907. PubMed ID: 29116280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins.
    Ware DC; Palmer HR; Pruijn FB; Anderson RF; Brothers PJ; Denny WA; Wilson WR
    Anticancer Drug Des; 1998 Mar; 13(2):81-103. PubMed ID: 9524553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells.
    Renfrew AK; Bryce NS; Hambley T
    Chemistry; 2015 Oct; 21(43):15224-34. PubMed ID: 26471438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.